ArticleInternational journal of molecular sciences2022
A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease.
Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- Identification of Potential FDA-Approved Inhibitors of SARS-CoV-2 Helicase Through a MultistepMedicinal chemistry (Shariqah (United Arab Emirates)) · 2025Article
- IntegratedCurrent medicinal chemistry · 2025Article
- Design and synthesis of new nicotinamides as immunomodulatory VEGFR-2 inhibitors and apoptosis inducers.Future medicinal chemistry · 2024Article
- Article
- Integrated study of Quercetin as a potent SARS-CoV-2 RdRp inhibitor: Binding interactions, MD simulations, and In vitro assays.PloS one · 2024Article
- Design, synthesis, docking, MD simulations, and anti-proliferative evaluation of thieno[2,3-Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Synthesis, biological evaluation and computer-aided discovery of new thiazolidine-2,4-dione derivatives as potential antitumor VEGFR-2 inhibitors.RSC advances · 2023Article
- Identification of new theobromine-based derivatives as potent VEGFR-2 inhibitors: design, semi-synthesis, biological evaluation, andRSC advances · 2023Article
- Design, synthesis,RSC advances · 2023Article
- Progress of the "Molecular Informatics" Section in 2022.International journal of molecular sciences · 2023Article
- Design, synthesis, anticancer evaluation, andRSC advances · 2023Article
- A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study.Life (Basel, Switzerland) · 2023Article
- Anticancer derivative of the natural alkaloid, theobromine, inhibiting EGFR protein: Computer-aided drug discovery approach.PloS one · 2023Article
- Green Synthesized Zinc Oxide Nanoparticles Based onMolecules (Basel, Switzerland) · 2022Article
- Design, synthesis, and biological evaluation of novel bioactive thalidomide analogs as anticancer immunomodulatory agents.RSC advances · 2022Article
- The Discovery of Potential SARS-CoV-2 Natural Inhibitors among 4924 African Metabolites Targeting the Papain-like Protease: A Multi-Phase In Silico Approach.Metabolites · 2022Article
- (Molecules (Basel, Switzerland) · 2022Article
- New Anticancer Theobromine Derivative Targeting EGFRMolecules (Basel, Switzerland) · 2022Article
- Discovery of Potential SARS-CoV-2 Papain-like Protease Natural Inhibitors Employing a Multi-Phase In Silico Approach.Life (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
Among a group of 310 natural antiviral natural metabolites, our team identified three compounds as the most potent natural inhibitors against the SARS-CoV-2 main protease (PDB ID: 5R84), M
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.